CDGEN1.16.40.5
ICANi001-A-1
General
Cell Line |
|
| hPSCreg name | ICANi001-A-1 |
| Cite as: | ICANi001-A-1 (RRID:CVCL_A5RF) |
| Alternative name(s) |
CDGEN1.16.40.5
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UCSFi001-A-89 (AICS-0097-102) UCSFi001-A-90 (AICS-0097-141) UCSFi001-A-91 (AICS-0097-157) UCSFi001-A-94 (AICS-0104-003) UCSFi001-A-95 (AICS-0104-085) UCSFi001-A-99 (AICS-0105-030) UCSFi001-A-A (AICS-0105-031) UCSFi001-A-B (AICS-0105-032) UCSFi001-A-C (AICS-0105-057) UCSFi001-A-G (AICS-0106-104) UCSFi001-A-H (AICS-0106-134) UCSFi001-A-I (AICS-0107-009) UCSFi001-A-J (AICS-0107-017) UCSFi001-A-M (AICS-0109-056) UCSFi001-A-O (AICS-0109-093) |
| Last update | 1st October 2021 |
| User feedback | |
Provider |
|
| Generator | INSERM U1166-Institute of Cardiometabolism And Nutrition (ICAN) |
| Owner | INSERM U1166-Institute of Cardiometabolism And Nutrition (ICAN) |
| Derivation country | France |
External Databases |
|
| BioSamples | SAMEA10203005 |
| Cellosaurus | CVCL_A5RF |
| Wikidata | Q107115416 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
External Databases (Donor) |
|
| BioSamples | SAMEA12775561 |
Ethics
Also have a look at the ethics information for the parental line
ICANi001-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
ICANi001-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method | Mechanically |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SOX2 |
Yes |
|
|
|||
| Alkaline Phosphatase |
Yes |
|
Self-renewal
Negative
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Karyotype CDGEN1-16-40.5
Passage number: 20
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.